New article in The Lancet aimed to study the effectiveness of one-dose of intranasal spray COVID-19 vaccine (dNS1-RBD) against symptomatic Omicron infections in real-world conditions. This prospective cohort study was led by ZhongShan Hospital, Fudan University (China) and Xiamen Clinical Research Center for Cancer Therapy (Xiamen, China).
“When administered as a booster to individuals with a history of inactivated COVID-19 vaccination, a single-dose of dNS1-RBD provides protection against infections requiring medical attention at least in the short-term after vaccination.”
